Fuzeon Discontinuations From Injection Reactions Remain Low At 48 Weeks
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche/Trimeris’ 48-week follow-up data for Fuzeon show a continued low rate of discontinuation due to injection site reactions.
You may also be interested in...
Fuzeon Sales Message: All Patients Benefit, But "The Earlier The Better"
Roche is emphasizing the benefit of early administration of its HIV therapy Fuzeon.
Fuzeon Increased Pneumonia Incidence Likely A "Specious" Finding – FDA
The increased incidence of bacterial pneumonia seen with Roche/Trimeris’ Fuzeon may be an artifact of the design of the pivotal trails, FDA suggested in review documents for the HIV therapy.
Fuzeon Sales Message: All Patients Benefit, But "The Earlier The Better"
Roche is emphasizing the benefit of early administration of its HIV therapy Fuzeon.